CXCL13 and neoplasm: As a control, anti-PD-L1-treated KPAR-challenged mice treated with a CD20-depleting antibody lost GC B cell responses systemically (Extended Data Fig. 5e) and anti-tumour antibodies completely (Fig. 3h), but were rendered insensitive to ICB, similarly to mice treated with a CXCL13-blocking antibody (Fig. 3g).